Medical Rationale Supporting Patient Access To Novel Oncology Combination Therapies
Considerations for the use of anthelminthic therapy for the treatment of neurocysticercosis
AK112 to validate its potential as next-generation IO therapy
OS Therapies Inc 2025年季度报告
Intra-Cellular Therapies Inc 2024年度报告
Taysha Gene Therapies Inc美股招股说明书(2025-05-28版)
Taysha Gene Therapies Inc 2024年度报告
BioRestorative Therapies Inc 2024年度报告